CA2398877A1 - Acides nucleiques, proteines et anticorps - Google Patents
Acides nucleiques, proteines et anticorps Download PDFInfo
- Publication number
- CA2398877A1 CA2398877A1 CA002398877A CA2398877A CA2398877A1 CA 2398877 A1 CA2398877 A1 CA 2398877A1 CA 002398877 A CA002398877 A CA 002398877A CA 2398877 A CA2398877 A CA 2398877A CA 2398877 A1 CA2398877 A1 CA 2398877A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- polypeptide
- polynucleotide
- cells
- cdna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 20
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 16
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 16
- 102000004169 proteins and genes Human genes 0.000 title claims description 15
- 108091005461 Nucleic proteins Proteins 0.000 title description 2
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 94
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 94
- 239000002157 polynucleotide Substances 0.000 claims abstract description 93
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 92
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 88
- 229920001184 polypeptide Polymers 0.000 claims abstract description 87
- 238000000034 method Methods 0.000 claims abstract description 27
- 239000013598 vector Substances 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 239000002299 complementary DNA Substances 0.000 claims description 54
- 125000003729 nucleotide group Chemical group 0.000 claims description 27
- 239000002773 nucleotide Substances 0.000 claims description 25
- 239000012634 fragment Substances 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 12
- 230000004071 biological effect Effects 0.000 claims description 4
- 238000004166 bioassay Methods 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims 8
- 230000037430 deletion Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 2
- 239000006228 supernatant Substances 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 65
- 230000003394 haemopoietic effect Effects 0.000 abstract description 37
- 210000000987 immune system Anatomy 0.000 abstract description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 25
- 210000001519 tissue Anatomy 0.000 abstract description 25
- 239000000427 antigen Substances 0.000 abstract description 23
- 102000036639 antigens Human genes 0.000 abstract description 23
- 108091007433 antigens Proteins 0.000 abstract description 23
- 201000010099 disease Diseases 0.000 abstract description 13
- 206010028980 Neoplasm Diseases 0.000 abstract description 12
- 239000000203 mixture Substances 0.000 abstract description 11
- 201000011510 cancer Diseases 0.000 abstract description 7
- 238000002560 therapeutic procedure Methods 0.000 abstract description 6
- 230000011132 hemopoiesis Effects 0.000 abstract description 5
- 210000002865 immune cell Anatomy 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 238000010189 synthetic method Methods 0.000 abstract description 4
- 206010027476 Metastases Diseases 0.000 abstract description 3
- 239000000556 agonist Substances 0.000 abstract description 3
- 239000005557 antagonist Substances 0.000 abstract description 3
- 238000002405 diagnostic procedure Methods 0.000 abstract description 3
- 238000010188 recombinant method Methods 0.000 abstract description 3
- 238000012216 screening Methods 0.000 abstract description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 28
- 210000001744 T-lymphocyte Anatomy 0.000 description 19
- 102000004127 Cytokines Human genes 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 108090000695 Cytokines Proteins 0.000 description 16
- 210000003719 b-lymphocyte Anatomy 0.000 description 15
- 229910052760 oxygen Inorganic materials 0.000 description 14
- 230000000295 complement effect Effects 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 239000011575 calcium Substances 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 210000003979 eosinophil Anatomy 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 210000003630 histaminocyte Anatomy 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000002955 immunomodulating agent Substances 0.000 description 6
- 229940121354 immunomodulator Drugs 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 210000003651 basophil Anatomy 0.000 description 5
- 230000002759 chromosomal effect Effects 0.000 description 5
- 108010057085 cytokine receptors Proteins 0.000 description 5
- 210000002443 helper t lymphocyte Anatomy 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 101000941356 Nostoc ellipsosporum Cyanovirin-N Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 241001442654 Percnon planissimum Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000001539 phagocyte Anatomy 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000972773 Aulopiformes Species 0.000 description 3
- 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 description 3
- 102000004631 Calcineurin Human genes 0.000 description 3
- 108010042955 Calcineurin Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 description 3
- 108010016648 Immunophilins Proteins 0.000 description 3
- 102000000521 Immunophilins Human genes 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 241000186362 Mycobacterium leprae Species 0.000 description 3
- 210000004241 Th2 cell Anatomy 0.000 description 3
- 208000016349 X-linked agammaglobulinemia Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 102000003675 cytokine receptors Human genes 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 230000007813 immunodeficiency Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000005007 innate immune system Anatomy 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 230000002969 morbid Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 3
- 229960004583 pranlukast Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 241001123946 Gaga Species 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102100020880 Kit ligand Human genes 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 description 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 1
- 241001408449 Asca Species 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 102000005738 B7 Antigens Human genes 0.000 description 1
- 108010045634 B7 Antigens Proteins 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 101150097247 CRT1 gene Proteins 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 101100382092 Clostridium botulinum D phage ntnha gene Proteins 0.000 description 1
- 101100004794 Clostridium botulinum ant gene Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229910019582 Cr V Inorganic materials 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000406799 Deto Species 0.000 description 1
- 206010051392 Diapedesis Diseases 0.000 description 1
- 101100383684 Drosophila melanogaster Cht10 gene Proteins 0.000 description 1
- 101100396994 Drosophila melanogaster Inos gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 241000989913 Gunnera petaloidea Species 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000040428 Heterodera iri Species 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000878213 Homo sapiens Inactive peptidyl-prolyl cis-trans isomerase FKBP6 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 241001440206 Homodes Species 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100036984 Inactive peptidyl-prolyl cis-trans isomerase FKBP6 Human genes 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 208000035342 Isolated congenital onychodysplasia Diseases 0.000 description 1
- 206010024227 Lepromatous leprosy Diseases 0.000 description 1
- 241000594011 Leuciscus leuciscus Species 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 101100462201 Mus musculus Opn4 gene Proteins 0.000 description 1
- 101500025412 Mus musculus Processed cyclic AMP-responsive element-binding protein 3-like protein 1 Proteins 0.000 description 1
- 101100201894 Mus musculus Rtn4ip1 gene Proteins 0.000 description 1
- 101100002888 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) asa-1 gene Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 1
- 101100113378 Oryza sativa subsp. japonica Cht9 gene Proteins 0.000 description 1
- 101150033824 PAA1 gene Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 101100409194 Rattus norvegicus Ppargc1b gene Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101150024537 Slc5a7 gene Proteins 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 101000588258 Taenia solium Paramyosin Proteins 0.000 description 1
- 101100273705 Talaromyces islandicus cctN gene Proteins 0.000 description 1
- IOYNQIMAUDJVEI-BMVIKAAMSA-N Tepraloxydim Chemical compound C1C(=O)C(C(=N/OC\C=C\Cl)/CC)=C(O)CC1C1CCOCC1 IOYNQIMAUDJVEI-BMVIKAAMSA-N 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- -1 calcium activated serine Chemical class 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 201000010158 nonsyndromic congenital nail disorder 7 Diseases 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 108010039177 polyphenylalanine Proteins 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229940083045 riax Drugs 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La présente invention concerne de nouveaux polynucléotides à association immunitaire/hématopoïétique et les polypeptides codés par ces polynucléotides, ici collectivement désignés comme <= antigènes immunitaires/hématopoïétiques >=, ainsi que l'utilisation de ces antigènes immunitaires/hématopoïétiques dans la détection de maladies et/ou troubles à association immunitaire/hématopoïétique, notamment la présence de cancer et de métastases cancéreuses de cellules d'origine hématopoïétique. Cette invention concerne plus spécifiquement des molécules d'acide nucléique à association immunitaire/hématopoïétique isolées, qui codent les nouveaux polypeptides à association immunitaire/hématopoïétique. La présente invention concerne également de nouveaux polypeptides et anticorps immunitaires/hématopoïétiques qui se lient à ces polypeptides. La présente invention concerne également des vecteurs, des cellules hôtes, ainsi que des procédés de recombinaison et de synthèse permettant de produire des polynucléotides et/ou polypeptides à association immunitaire/hématopoïétique humains. La présente invention concerne également des procédés diagnostiques et thérapeutiques permettant de diagnostiquer, de traiter, de prévenir et/ou de pronostiquer des troubles associés au système ou aux cellules immunitaires et des tissus associés à l'hématopoïèse, comprenant des cancers de cellules d'origine hématopoïétique, ainsi que des procédés thérapeutiques permettant de traiter de tels troubles. La présente invention concerne également des procédés de criblage permettant d'identifier des agonistes et des antagonistes des polynucléotides et polypeptides selon cette invention. En outre, cette invention concerne des procédés et/ou des compositions permettant d'inhiber la production et le fonctionnement des polypeptides selon cette invention.
Applications Claiming Priority (235)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17906500P | 2000-01-31 | 2000-01-31 | |
US60/179,065 | 2000-01-31 | ||
US18062800P | 2000-02-04 | 2000-02-04 | |
US60/180,628 | 2000-02-04 | ||
US18466400P | 2000-02-24 | 2000-02-24 | |
US60/184,664 | 2000-02-24 | ||
US18635000P | 2000-03-02 | 2000-03-02 | |
US60/186,350 | 2000-03-02 | ||
US18987400P | 2000-03-16 | 2000-03-16 | |
US60/189,874 | 2000-03-16 | ||
US19007600P | 2000-03-17 | 2000-03-17 | |
US60/190,076 | 2000-03-17 | ||
US19812300P | 2000-04-18 | 2000-04-18 | |
US60/198,123 | 2000-04-18 | ||
US20551500P | 2000-05-19 | 2000-05-19 | |
US60/205,515 | 2000-05-19 | ||
US20946700P | 2000-06-07 | 2000-06-07 | |
US60/209,467 | 2000-06-07 | ||
US21488600P | 2000-06-28 | 2000-06-28 | |
US60/214,886 | 2000-06-28 | ||
US21513500P | 2000-06-30 | 2000-06-30 | |
US60/215,135 | 2000-06-30 | ||
US21688000P | 2000-07-07 | 2000-07-07 | |
US21664700P | 2000-07-07 | 2000-07-07 | |
US60/216,880 | 2000-07-07 | ||
US60/216,647 | 2000-07-07 | ||
US21749600P | 2000-07-11 | 2000-07-11 | |
US21748700P | 2000-07-11 | 2000-07-11 | |
US60/217,487 | 2000-07-11 | ||
US60/217,496 | 2000-07-11 | ||
US21829000P | 2000-07-14 | 2000-07-14 | |
US60/218,290 | 2000-07-14 | ||
US22096400P | 2000-07-26 | 2000-07-26 | |
US22096300P | 2000-07-26 | 2000-07-26 | |
US60/220,963 | 2000-07-26 | ||
US60/220,964 | 2000-07-26 | ||
US22575700P | 2000-08-14 | 2000-08-14 | |
US22451800P | 2000-08-14 | 2000-08-14 | |
US22575800P | 2000-08-14 | 2000-08-14 | |
US22451900P | 2000-08-14 | 2000-08-14 | |
US22526700P | 2000-08-14 | 2000-08-14 | |
US22527000P | 2000-08-14 | 2000-08-14 | |
US22521400P | 2000-08-14 | 2000-08-14 | |
US22575900P | 2000-08-14 | 2000-08-14 | |
US22544700P | 2000-08-14 | 2000-08-14 | |
US22521300P | 2000-08-14 | 2000-08-14 | |
US22526600P | 2000-08-14 | 2000-08-14 | |
US22526800P | 2000-08-14 | 2000-08-14 | |
US60/225,267 | 2000-08-14 | ||
US60/225,213 | 2000-08-14 | ||
US60/225,268 | 2000-08-14 | ||
US60/224,518 | 2000-08-14 | ||
US60/225,266 | 2000-08-14 | ||
US60/225,447 | 2000-08-14 | ||
US60/224,519 | 2000-08-14 | ||
US60/225,270 | 2000-08-14 | ||
US60/225,759 | 2000-08-14 | ||
US60/225,214 | 2000-08-14 | ||
US60/225,758 | 2000-08-14 | ||
US60/225,757 | 2000-08-14 | ||
US22627900P | 2000-08-18 | 2000-08-18 | |
US60/226,279 | 2000-08-18 | ||
US22686800P | 2000-08-22 | 2000-08-22 | |
US22718200P | 2000-08-22 | 2000-08-22 | |
US22668100P | 2000-08-22 | 2000-08-22 | |
US60/226,681 | 2000-08-22 | ||
US60/227,182 | 2000-08-22 | ||
US60/226,868 | 2000-08-22 | ||
US22700900P | 2000-08-23 | 2000-08-23 | |
US60/227,009 | 2000-08-23 | ||
US22892400P | 2000-08-30 | 2000-08-30 | |
US60/228,924 | 2000-08-30 | ||
US22934300P | 2000-09-01 | 2000-09-01 | |
US22928700P | 2000-09-01 | 2000-09-01 | |
US22934500P | 2000-09-01 | 2000-09-01 | |
US22934400P | 2000-09-01 | 2000-09-01 | |
US60/229,287 | 2000-09-01 | ||
US60/229,343 | 2000-09-01 | ||
US60/229,345 | 2000-09-01 | ||
US60/229,344 | 2000-09-01 | ||
US22951300P | 2000-09-05 | 2000-09-05 | |
US22950900P | 2000-09-05 | 2000-09-05 | |
US60/229,513 | 2000-09-05 | ||
US60/229,509 | 2000-09-05 | ||
US23043700P | 2000-09-06 | 2000-09-06 | |
US23043800P | 2000-09-06 | 2000-09-06 | |
US60/230,437 | 2000-09-06 | ||
US60/230,438 | 2000-09-06 | ||
US23124400P | 2000-09-08 | 2000-09-08 | |
US23124300P | 2000-09-08 | 2000-09-08 | |
US23141300P | 2000-09-08 | 2000-09-08 | |
US23124200P | 2000-09-08 | 2000-09-08 | |
US23208100P | 2000-09-08 | 2000-09-08 | |
US23208000P | 2000-09-08 | 2000-09-08 | |
US23141400P | 2000-09-08 | 2000-09-08 | |
US60/231,244 | 2000-09-08 | ||
US60/231,413 | 2000-09-08 | ||
US60/232,080 | 2000-09-08 | ||
US60/231,414 | 2000-09-08 | ||
US60/231,242 | 2000-09-08 | ||
US60/231,243 | 2000-09-08 | ||
US60/232,081 | 2000-09-08 | ||
US23196800P | 2000-09-12 | 2000-09-12 | |
US60/231,968 | 2000-09-12 | ||
US23239700P | 2000-09-14 | 2000-09-14 | |
US23240000P | 2000-09-14 | 2000-09-14 | |
US23240100P | 2000-09-14 | 2000-09-14 | |
US23239800P | 2000-09-14 | 2000-09-14 | |
US23306500P | 2000-09-14 | 2000-09-14 | |
US23306400P | 2000-09-14 | 2000-09-14 | |
US23306300P | 2000-09-14 | 2000-09-14 | |
US23239900P | 2000-09-14 | 2000-09-14 | |
US60/232,400 | 2000-09-14 | ||
US60/233,064 | 2000-09-14 | ||
US60/232,397 | 2000-09-14 | ||
US60/232,401 | 2000-09-14 | ||
US60/232,399 | 2000-09-14 | ||
US60/232,398 | 2000-09-14 | ||
US60/233,065 | 2000-09-14 | ||
US60/233,063 | 2000-09-14 | ||
US23427400P | 2000-09-21 | 2000-09-21 | |
US23422300P | 2000-09-21 | 2000-09-21 | |
US60/234,223 | 2000-09-21 | ||
US60/234,274 | 2000-09-21 | ||
US23499700P | 2000-09-25 | 2000-09-25 | |
US23499800P | 2000-09-25 | 2000-09-25 | |
US60/234,998 | 2000-09-25 | ||
US60/234,997 | 2000-09-25 | ||
US23548400P | 2000-09-26 | 2000-09-26 | |
US60/235,484 | 2000-09-26 | ||
US23583600P | 2000-09-27 | 2000-09-27 | |
US23583400P | 2000-09-27 | 2000-09-27 | |
US60/235,836 | 2000-09-27 | ||
US60/235,834 | 2000-09-27 | ||
US23636700P | 2000-09-29 | 2000-09-29 | |
US23636800P | 2000-09-29 | 2000-09-29 | |
US23637000P | 2000-09-29 | 2000-09-29 | |
US23632700P | 2000-09-29 | 2000-09-29 | |
US23636900P | 2000-09-29 | 2000-09-29 | |
US60/236,367 | 2000-09-29 | ||
US60/236,327 | 2000-09-29 | ||
US60/236,368 | 2000-09-29 | ||
US60/236,370 | 2000-09-29 | ||
US60/236,369 | 2000-09-29 | ||
US23703800P | 2000-10-02 | 2000-10-02 | |
US23680200P | 2000-10-02 | 2000-10-02 | |
US23703700P | 2000-10-02 | 2000-10-02 | |
US23704000P | 2000-10-02 | 2000-10-02 | |
US23703900P | 2000-10-02 | 2000-10-02 | |
US60/237,038 | 2000-10-02 | ||
US60/237,040 | 2000-10-02 | ||
US60/237,037 | 2000-10-02 | ||
US60/237,039 | 2000-10-02 | ||
US60/236,802 | 2000-10-02 | ||
US23993500P | 2000-10-13 | 2000-10-13 | |
US23993700P | 2000-10-13 | 2000-10-13 | |
US60/239,937 | 2000-10-13 | ||
US60/239,935 | 2000-10-13 | ||
US24122100P | 2000-10-20 | 2000-10-20 | |
US24182600P | 2000-10-20 | 2000-10-20 | |
US24180900P | 2000-10-20 | 2000-10-20 | |
US24178500P | 2000-10-20 | 2000-10-20 | |
US24180800P | 2000-10-20 | 2000-10-20 | |
US24178700P | 2000-10-20 | 2000-10-20 | |
US24178600P | 2000-10-20 | 2000-10-20 | |
US24096000P | 2000-10-20 | 2000-10-20 | |
US60/241,809 | 2000-10-20 | ||
US60/241,786 | 2000-10-20 | ||
US60/241,808 | 2000-10-20 | ||
US60/241,826 | 2000-10-20 | ||
US60/241,785 | 2000-10-20 | ||
US60/241,221 | 2000-10-20 | ||
US60/240,960 | 2000-10-20 | ||
US60/241,787 | 2000-10-20 | ||
US24461700P | 2000-11-01 | 2000-11-01 | |
US60/244,617 | 2000-11-01 | ||
US24652600P | 2000-11-08 | 2000-11-08 | |
US24652500P | 2000-11-08 | 2000-11-08 | |
US24652700P | 2000-11-08 | 2000-11-08 | |
US24647600P | 2000-11-08 | 2000-11-08 | |
US24661100P | 2000-11-08 | 2000-11-08 | |
US24647500P | 2000-11-08 | 2000-11-08 | |
US24647400P | 2000-11-08 | 2000-11-08 | |
US24652800P | 2000-11-08 | 2000-11-08 | |
US24647700P | 2000-11-08 | 2000-11-08 | |
US24661000P | 2000-11-08 | 2000-11-08 | |
US24653200P | 2000-11-08 | 2000-11-08 | |
US60/246,525 | 2000-11-08 | ||
US60/246,475 | 2000-11-08 | ||
US60/246,526 | 2000-11-08 | ||
US60/246,609 | 2000-11-08 | ||
US60/246,474 | 2000-11-08 | ||
US60/246,611 | 2000-11-08 | ||
US60/246,527 | 2000-11-08 | ||
US60/246,613 | 2000-11-08 | ||
US60/246,478 | 2000-11-08 | ||
US60/246,477 | 2000-11-08 | ||
US60/246,476 | 2000-11-08 | ||
US60/246,532 | 2000-11-08 | ||
US60/246,528 | 2000-11-08 | ||
US60/246,610 | 2000-11-08 | ||
US60/246,524 | 2000-11-08 | ||
US60/246,523 | 2000-11-08 | ||
US60/249,211 | 2000-11-17 | ||
US60/249,244 | 2000-11-17 | ||
US60/249,212 | 2000-11-17 | ||
US60/249,214 | 2000-11-17 | ||
US60/249,265 | 2000-11-17 | ||
US60/249,213 | 2000-11-17 | ||
US60/249,217 | 2000-11-17 | ||
US60/249,264 | 2000-11-17 | ||
US60/249,216 | 2000-11-17 | ||
US60/249,208 | 2000-11-17 | ||
US60/249,245 | 2000-11-17 | ||
US60/249,207 | 2000-11-17 | ||
US60/249,300 | 2000-11-17 | ||
US60/249,299 | 2000-11-17 | ||
US60/249,218 | 2000-11-17 | ||
US60/249,215 | 2000-11-17 | ||
US60/249,297 | 2000-11-17 | ||
US60/249,209 | 2000-11-17 | ||
US60/249,210 | 2000-11-17 | ||
US60/250,160 | 2000-12-01 | ||
US60/250,391 | 2000-12-01 | ||
US60/251,988 | 2000-12-05 | ||
US60/251,030 | 2000-12-05 | ||
US60/256,719 | 2000-12-05 | ||
US60/251,479 | 2000-12-06 | ||
US60/251,869 | 2000-12-08 | ||
US60/251,856 | 2000-12-08 | ||
US60/251,990 | 2000-12-08 | ||
US60/251,989 | 2000-12-08 | ||
US60/251,868 | 2000-12-08 | ||
US60/254,097 | 2000-12-11 | ||
US60/259,678 | 2001-01-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2398877A1 true CA2398877A1 (fr) | 2001-08-09 |
Family
ID=27587117
Family Applications (37)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002395666A Withdrawn CA2395666A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395729A Pending CA2395729A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395699A Pending CA2395699A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002394039A Abandoned CA2394039A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395827A Withdrawn CA2395827A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395734A Withdrawn CA2395734A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002398877A Withdrawn CA2398877A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392438A Abandoned CA2392438A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395787A Withdrawn CA2395787A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002397407A Withdrawn CA2397407A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002393912A Withdrawn CA2393912A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395403A Withdrawn CA2395403A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395654A Withdrawn CA2395654A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395885A Withdrawn CA2395885A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002398411A Withdrawn CA2398411A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395849A Pending CA2395849A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395872A Withdrawn CA2395872A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395693A Pending CA2395693A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392751A Abandoned CA2392751A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395858A Withdrawn CA2395858A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002393652A Withdrawn CA2393652A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392398A Abandoned CA2392398A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002397839A Withdrawn CA2397839A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395295A Withdrawn CA2395295A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395671A Withdrawn CA2395671A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395738A Withdrawn CA2395738A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002393618A Abandoned CA2393618A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392428A Abandoned CA2392428A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395398A Withdrawn CA2395398A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines, et anticorps |
CA002395178A Withdrawn CA2395178A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392422A Abandoned CA2392422A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392450A Abandoned CA2392450A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395724A Pending CA2395724A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002393002A Withdrawn CA2393002A1 (fr) | 2000-01-31 | 2001-01-17 | Acides ncleiques, proteines et anticorps |
CA002394841A Withdrawn CA2394841A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392757A Abandoned CA2392757A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395816A Withdrawn CA2395816A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002395666A Withdrawn CA2395666A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395729A Pending CA2395729A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395699A Pending CA2395699A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002394039A Abandoned CA2394039A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395827A Withdrawn CA2395827A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395734A Withdrawn CA2395734A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
Family Applications After (30)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002392438A Abandoned CA2392438A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395787A Withdrawn CA2395787A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002397407A Withdrawn CA2397407A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002393912A Withdrawn CA2393912A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395403A Withdrawn CA2395403A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395654A Withdrawn CA2395654A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395885A Withdrawn CA2395885A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002398411A Withdrawn CA2398411A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395849A Pending CA2395849A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395872A Withdrawn CA2395872A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395693A Pending CA2395693A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392751A Abandoned CA2392751A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395858A Withdrawn CA2395858A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002393652A Withdrawn CA2393652A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392398A Abandoned CA2392398A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002397839A Withdrawn CA2397839A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395295A Withdrawn CA2395295A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395671A Withdrawn CA2395671A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395738A Withdrawn CA2395738A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002393618A Abandoned CA2393618A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392428A Abandoned CA2392428A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395398A Withdrawn CA2395398A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines, et anticorps |
CA002395178A Withdrawn CA2395178A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392422A Abandoned CA2392422A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392450A Abandoned CA2392450A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395724A Pending CA2395724A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002393002A Withdrawn CA2393002A1 (fr) | 2000-01-31 | 2001-01-17 | Acides ncleiques, proteines et anticorps |
CA002394841A Withdrawn CA2394841A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392757A Abandoned CA2392757A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395816A Withdrawn CA2395816A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
Country Status (3)
Country | Link |
---|---|
AU (16) | AU2001241409A1 (fr) |
CA (37) | CA2395666A1 (fr) |
WO (48) | WO2001055355A1 (fr) |
Families Citing this family (271)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002008288A2 (fr) * | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides |
US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7579160B2 (en) | 1998-03-18 | 2009-08-25 | Corixa Corporation | Methods for the detection of cervical cancer |
US6960570B2 (en) | 1998-03-18 | 2005-11-01 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US7258860B2 (en) | 1998-03-18 | 2007-08-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6706262B1 (en) | 1998-03-18 | 2004-03-16 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
CA2328496C (fr) | 1998-05-15 | 2016-01-05 | Genentech, Inc. | Polypeptides homologues de il-17 et utilisations therapeutiques de ceux-ci |
US7771719B1 (en) | 2000-01-11 | 2010-08-10 | Genentech, Inc. | Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E |
US6929938B2 (en) | 2001-08-15 | 2005-08-16 | Millennium Pharmaceuticals, Inc. | 25501, a human transferase family member and uses therefor |
WO2000050565A2 (fr) * | 1999-02-25 | 2000-08-31 | Thomas Jefferson University | Compositions, kits et procedes concernant le gene fez1 de l'homme, nouveau gene suppresseur des tumeurs |
US7141417B1 (en) | 1999-02-25 | 2006-11-28 | Thomas Jefferson University | Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene |
EP1157038A4 (fr) * | 1999-02-26 | 2005-01-19 | Smithkline Beecham Corp | Clonage du recepteur 7tm (axor 17) du type p2y |
WO2000056881A1 (fr) * | 1999-03-23 | 2000-09-28 | Human Genome Sciences, Inc. | 48 proteines humaines secretees |
CA2365601A1 (fr) | 1999-03-29 | 2000-10-05 | Kansai Technology Licensing Organization Co., Ltd. | Nouvelle cytidine desaminase |
EP1637541B1 (fr) * | 1999-09-01 | 2010-03-03 | Genentech, Inc. | Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci |
US20020151047A1 (en) * | 2001-01-08 | 2002-10-17 | Yi Hu | Novel human protease and polynucleotides encoding the same |
AU1238201A (en) * | 1999-10-27 | 2001-05-08 | Millennium Pharmaceuticals, Inc. | Novel molecules and the card-related protein family and uses thereof |
US6893818B1 (en) | 1999-10-28 | 2005-05-17 | Agensys, Inc. | Gene upregulated in cancers of the prostate |
US7005499B1 (en) * | 1999-11-18 | 2006-02-28 | Genentech, Inc. | Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same |
EP1878795A3 (fr) * | 1999-11-30 | 2008-01-23 | Genentech, Inc. | Compositions et procédés pour le traitement de maladies liées au système immunitaire |
EP1250426A2 (fr) * | 1999-12-01 | 2002-10-23 | Genentech Inc. | Polypeptides transmembranaires et secretes et les acides nucleiques codant ceux-ci |
CN1300781A (zh) * | 1999-12-22 | 2001-06-27 | 上海博德基因开发有限公司 | 一种新的多肽-人shc蛋白43和编码这种多肽的多核苷酸 |
US20040043397A1 (en) | 2000-01-11 | 2004-03-04 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
AU2001237973B2 (en) | 2000-01-26 | 2006-09-07 | Agensys, Inc. | 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer |
US6953682B2 (en) | 2000-02-10 | 2005-10-11 | Millennium Pharmaceuticals, Inc. | Nucleic acid sequences encoding adenylate kinase, phospholipid scramblase-like, DNA fragmentation factor-like, phosphatidylserine synthase-like, and atpase-like molecules and uses therefor |
US7078205B2 (en) | 2000-02-17 | 2006-07-18 | Millennium Pharmaceuticals, Inc. | Nucleic acid sequences encoding melanoma associated antigen molecules, aminotransferase molecules, atpase molecules, acyltransferase molecules, pyridoxal-phosphate dependent enzyme molecules and uses therefor |
US20020082212A1 (en) * | 2000-07-20 | 2002-06-27 | Millennium Pharmaceuticals, Inc. | 7716, a novel human ATPase and uses therefor |
US20020090705A1 (en) * | 2000-07-14 | 2002-07-11 | Rachel Meyers | 62088, a novel human nucleoside phosphatase family member and uses thereof |
US20020055159A1 (en) * | 2000-06-15 | 2002-05-09 | Meyers Rachel A. | 23680,a novel human aminotransferase and uses therefor |
US7718397B2 (en) | 2000-03-21 | 2010-05-18 | Genentech, Inc. | Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof |
AU2001250980A1 (en) * | 2000-03-23 | 2001-10-03 | Carmela Beger | Brca-1 regulators and methods of use |
AU2001245974A1 (en) | 2000-03-24 | 2001-10-08 | Millennium Pharmaceuticals, Inc. | 3714, 16742, 23546, and 13887 novel protein kinase molecules and uses therefor |
US20030198953A1 (en) * | 2000-03-30 | 2003-10-23 | Spytek Kimberly A. | Novel proteins and nucleic acids encoding same |
US7632929B2 (en) | 2000-04-20 | 2009-12-15 | The Board Of Trustees Of The University Of Arkansas | Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof |
JP2004511205A (ja) | 2000-04-25 | 2004-04-15 | レキシコン・ジェネティクス・インコーポレーテッド | 新規ヒトキナーゼプロテインおよびそれをコードするポリヌクレオチド |
AU2001257407A1 (en) * | 2000-04-26 | 2001-11-07 | Millennium Pharmaceuticals, Inc. | 21657, a human short-chain dehydrogenase and uses thereof |
US6808876B1 (en) * | 2000-05-02 | 2004-10-26 | Immusol, Inc. | Cellular regulators of infectious agents and methods of use |
WO2001085921A2 (fr) * | 2000-05-12 | 2001-11-15 | Merck Patent Gmbh | Nouvelle serine-threonine kinase-4 |
EP1158001B1 (fr) * | 2000-05-26 | 2007-11-14 | F. Hoffmann-La Roche Ag | Un acide nucléique produit excessivement dans des cellules tumorales humaines, une protéine codée par ledit acide nucléique et un procédé de diagnose de tumeurs |
AU7634301A (en) * | 2000-05-26 | 2001-12-03 | Bayer Aktiengesellschaft | Regulation of human p78-like serine/threonine kinase |
DE10027170A1 (de) * | 2000-05-31 | 2001-12-13 | Schering Ag | Humanes PEM als Target für die Fertilitätskontrolle |
US7098311B2 (en) * | 2000-06-02 | 2006-08-29 | Brigham And Women's Hospital | Fusion of jAZF1 and jjAZ1 genes in endometrial stromal tumors |
US20030096969A1 (en) | 2000-06-02 | 2003-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU6531101A (en) * | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU6604901A (en) * | 2000-06-05 | 2001-12-17 | Bayer Aktiengesellschaft | Regulation of human hm74-like g protein coupled receptor |
US6323016B1 (en) | 2000-06-09 | 2001-11-27 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
EP1287029A2 (fr) * | 2000-06-09 | 2003-03-05 | Corixa Corporation | Compositions et procedes pour la therapie et le diagnostic du cancer du colon |
WO2001096546A2 (fr) * | 2000-06-16 | 2001-12-20 | Incyte Genomics, Inc. | Proteine-phosphatases |
EP2075253A1 (fr) * | 2000-06-23 | 2009-07-01 | Genentech, Inc. | Méthodes et composés pour la diagnose et le traitement de troubles associés à l'angiogenèse |
WO2002000861A2 (fr) * | 2000-06-26 | 2002-01-03 | Millennium Pharmaceuticals, Inc. | 46619, une nouvelle synthase beta-cetoacyle et utilisations de cette derniere |
AU2001270215A1 (en) * | 2000-06-27 | 2002-01-08 | Curagen Corporation | Novel polynucleotides and polypeptides encoded thereby |
US7094587B2 (en) | 2000-06-27 | 2006-08-22 | Millennium Pharmaceuticals, Inc. | 16002 Molecules and uses therefor |
US6774223B2 (en) | 2000-06-28 | 2004-08-10 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
WO2002002761A2 (fr) * | 2000-06-30 | 2002-01-10 | Millennium Pharmaceuticals, Inc. | 57658, nouvelle uridine kinase humaine et utilisations correspondantes |
AU2001271843A1 (en) * | 2000-07-07 | 2002-01-21 | Incyte Genomics, Inc. | Gtp-binding proteins |
AU2001273239A1 (en) * | 2000-07-07 | 2002-01-21 | Incyte Genomics, Inc. | Transporters and ion channels |
EP1303620A2 (fr) * | 2000-07-18 | 2003-04-23 | Bayer Aktiengesellschaft | Regulation de protease a serine humaine de type desc1 |
US6740751B2 (en) | 2000-07-18 | 2004-05-25 | Board Of Regents, The University Of Texas System | Methods and compositions for stabilizing microtubules and intermediate filaments in striated muscle cells |
AU8762901A (en) * | 2000-07-25 | 2002-02-05 | Merck Patent Gmbh | Novel protein containing ring finger domaine r1p4 |
AU2001277202A1 (en) * | 2000-07-26 | 2002-02-05 | Applied Genomics, Inc. | Bstp-ras/rerg protein and related reagents and methods of use thereof |
AU2001277200A1 (en) * | 2000-07-26 | 2002-02-05 | Applied Genomics, Inc. | Bstp-cad protein and related reagents and methods of use thereof |
EP1657254A3 (fr) * | 2000-08-01 | 2006-06-07 | Genentech, Inc. | Polypeptide, acides nucléiques le codant, et leur utilisation pour le diagnostic du cancer |
US7335732B2 (en) | 2000-08-01 | 2008-02-26 | Genentech, Inc. | PRO9799 polypeptides |
EP1315431A1 (fr) * | 2000-08-02 | 2003-06-04 | Millennium Pharmaceuticals, Inc. | Membre de la famille du facteur de liberation du gtp humain (15368) et ses utilisations |
WO2002010217A2 (fr) | 2000-08-02 | 2002-02-07 | The Johns Hopkins University | Profils d'expression de cellules endotheliales |
WO2002012330A2 (fr) * | 2000-08-04 | 2002-02-14 | Zymogenetics, Inc. | Zzp1, proteine humaine secretee |
US6943245B2 (en) | 2000-08-10 | 2005-09-13 | Board Of Regents, The University Of Texas System | Tumor suppressor CAR-1 |
JP2004506422A (ja) * | 2000-08-11 | 2004-03-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 新規マイトジェン活性化キナーゼ |
EP1326985A1 (fr) * | 2000-08-18 | 2003-07-16 | MERCK PATENT GmbH | Identification d'un gene d'acetyltransferase n-terminale humaine |
US6706513B2 (en) | 2000-08-21 | 2004-03-16 | Bristol-Myers Squibb Company | Adenosine deaminase homolog |
JP2004519217A (ja) * | 2000-08-21 | 2004-07-02 | インサイト・ゲノミックス・インコーポレイテッド | 微小管関連タンパク質およびチューブリン |
WO2002016579A2 (fr) * | 2000-08-24 | 2002-02-28 | Eli Lilly And Company | Acides nucleiques, vecteurs, cellules hotes, polypeptides et utilisations de ces derniers |
CA2705366A1 (fr) * | 2000-08-28 | 2002-03-07 | Agensys, Inc. | Acide nucleique et proteine correspondante denommes 85p1b3 utilises dans le traitement et la detection de cancers |
CA2420902A1 (fr) * | 2000-08-28 | 2002-03-07 | Craig A. Rosen | 18 proteines humaines secretees |
AU2001284176A1 (en) * | 2000-08-28 | 2002-03-13 | Astrazeneca Ab | Molecules involved in the regulation of insulin in resistance syndrome (irs) |
AU2002210464A1 (en) * | 2000-08-30 | 2002-03-13 | Bayer Aktiengesellschaft | Regulation of human aminotransferase-like enzyme |
WO2002018577A2 (fr) * | 2000-08-30 | 2002-03-07 | Millennium Pharmaceuticals, Inc. | Nouveau facteur de terminaison du gtp humain 48921 et ses utilisations |
WO2002018552A2 (fr) * | 2000-08-30 | 2002-03-07 | Bayer Aktiengesellschaft | Regulation d'enzyme humaine de type aminotransferase |
AU2001286714A1 (en) * | 2000-08-30 | 2002-03-13 | Millennium Pharmaceuticals, Inc. | 54370, a novel human sulfate transporter and uses therefor |
WO2002018582A2 (fr) * | 2000-08-31 | 2002-03-07 | Millennium Pharmaceuticals, Inc. | 62112, nouvelle deshydrogenase humaine et ses utilisations |
US7153669B2 (en) | 2000-09-05 | 2006-12-26 | Amgen Inc. | Nucleic acids encoding MK61 receptors |
CA2421265A1 (fr) * | 2000-09-05 | 2002-03-14 | Incyte Genomics, Inc. | Molecules utilisees a des fins diagnostiques et therapeutiques |
US20020142464A1 (en) * | 2000-09-08 | 2002-10-03 | Millennium Pharmaceuticals, Inc. | 38646, a novel guanine nucleotide exchange factor and uses therefor |
US6372468B1 (en) * | 2000-09-14 | 2002-04-16 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
US6391606B1 (en) * | 2000-09-14 | 2002-05-21 | Pe Corporation | Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof |
US20040048245A1 (en) * | 2000-10-05 | 2004-03-11 | Shimkets Richard A. | Novel human proteins, polynucleotides encoding them and methods of using the same |
WO2002031126A2 (fr) * | 2000-10-11 | 2002-04-18 | Bayer Aktiengesellschaft | Regulation d'une peptidyl-prolyl cis-trans isomerase de type cyclophiline humaine |
WO2002031132A2 (fr) * | 2000-10-11 | 2002-04-18 | Millennium Pharmaceuticals, Inc. | Nouvel element de la famille des phosphatases humaines a double specificite, appele 8843, et utilisation de ce dernier |
US20020064831A1 (en) * | 2000-10-12 | 2002-05-30 | The Texas A&M University System | Nucleic acid sequences encoding CMG proteins, CMG proteins, and methods for their use |
EP1474528A4 (fr) * | 2000-10-13 | 2006-06-14 | Protein Design Labs Inc | Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate |
US6531297B2 (en) * | 2000-10-20 | 2003-03-11 | Applera Corporation | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
WO2002062945A2 (fr) | 2000-10-25 | 2002-08-15 | Diadexus, Inc. | Compositions et techniques relatives a des genes et a des proteines specifiques du poumon |
WO2002036781A2 (fr) * | 2000-10-31 | 2002-05-10 | Bayer Aktiengesellschaft | Regulation de la glutathione-s-transferase humaine |
WO2002038743A2 (fr) * | 2000-11-09 | 2002-05-16 | Glaxo Group Limited | Enzyme |
EP1349934A2 (fr) | 2000-11-20 | 2003-10-08 | Diadexus, Inc. | Compositions et methodes relatives a des genes et des proteines specifiques aux seins |
AU2001297765A1 (en) * | 2000-12-05 | 2002-10-21 | Incyte Genomics, Inc. | Ligases |
US7776523B2 (en) | 2000-12-07 | 2010-08-17 | Novartis Vaccines And Diagnostics, Inc. | Endogenous retroviruses up-regulated in prostate cancer |
EP1339845A2 (fr) | 2000-12-07 | 2003-09-03 | ZymoGenetics, Inc. | Proteine associee au complement adipocyte zacrp3x2 |
WO2002048328A2 (fr) * | 2000-12-14 | 2002-06-20 | Pe Corporation (Ny) | Proteines kinases humaines isolees, molecules d'acide nucleique codant des proteines kinases humaines et utilisations associees |
US20020142376A1 (en) * | 2000-12-20 | 2002-10-03 | Gennady Merkulov | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
IL155687A0 (en) | 2000-12-22 | 2003-11-23 | Bristol Myers Squibb Co | Polynucleotides encoding hlrrsi1 polypeptides |
US7892730B2 (en) | 2000-12-22 | 2011-02-22 | Sagres Discovery, Inc. | Compositions and methods for cancer |
US6423521B1 (en) | 2000-12-28 | 2002-07-23 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
WO2002053591A1 (fr) * | 2000-12-30 | 2002-07-11 | Lion Bioscience Ag | Cofacteur de recepteur nucleaire mammalien cf12 et ses procedes d'utilisation |
US20030219739A1 (en) * | 2001-01-30 | 2003-11-27 | Glass David J. | Novel nucleic acid and polypeptide molecules |
WO2002098917A2 (fr) * | 2001-02-12 | 2002-12-12 | Curagen Corporation | Proteines, polynucleotides codant pour lesdites proteines et methodes d'utilisation desdites proteines |
EP1637601A3 (fr) * | 2001-02-21 | 2006-03-29 | Curagen Corporation | Protéines , polynucléotides codant pour ces protéines et procédés d'utilisation |
US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
AU2002250143A1 (en) * | 2001-03-16 | 2002-10-03 | Eli Lilly And Company | Lp mammalian proteins; related reagents |
US6913904B2 (en) * | 2001-03-27 | 2005-07-05 | Applera Corporation | Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof |
AU2002258626B2 (en) | 2001-04-10 | 2007-01-18 | Agensys, Inc. | Nucleid acid and corresponding protein entitled 158P3D2 useful in treatment and detection of cancer |
EP2280030A3 (fr) | 2001-04-10 | 2011-06-15 | Agensys, Inc. | Acides nucléiques et protéines correspondantes utiles dans la détection et le traitement des différents cancers |
EP1573022B1 (fr) | 2001-04-10 | 2011-06-08 | Agensys, Inc. | Acide nucleique et proteine correspondante intitulee 184p1e2, utilises dans le traitement et la detection de cancers |
WO2002086113A2 (fr) * | 2001-04-24 | 2002-10-31 | Isis Innovation Ltd | Enzyme et marqueur snp pour le depistage d'une maladie |
JPWO2002088175A1 (ja) * | 2001-04-24 | 2004-08-19 | 大塚製薬株式会社 | クローン病抗体結合性ペプチド及びクローン病の検査方法 |
KR100882762B1 (ko) | 2001-05-07 | 2009-02-09 | 시오노기세이야쿠가부시키가이샤 | 혈관신생 마커로서 사용되는 폴리펩티드 및 이의 dna |
AU2002314048A1 (en) * | 2001-05-09 | 2002-11-18 | Bayer Aktiengesellschaft | Regulation of human phosphatidic acid phosphatase type 2c-like protein |
US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
US7235358B2 (en) * | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
WO2003000901A2 (fr) * | 2001-06-26 | 2003-01-03 | Decode Genetics Ehf. | Acides nucleiques codant des proteines kinases |
US20030120040A1 (en) | 2001-06-29 | 2003-06-26 | Genentech, Inc. | Secreted and Transmembrane polypeptides and nucleic acids encoding the same |
GB2399086A (en) * | 2001-08-02 | 2004-09-08 | Aeomica Inc | Human zinc finger containing gene MDZ4 |
WO2003031568A2 (fr) * | 2001-08-17 | 2003-04-17 | Incyte Genomics, Inc. | Molecules de signalisation intracellulaire |
US7270960B2 (en) | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
WO2003023063A1 (fr) * | 2001-09-07 | 2003-03-20 | Sankyo Company, Limited | Methode d'estimation du risque d'apparition de diabetes |
WO2003025175A2 (fr) * | 2001-09-17 | 2003-03-27 | Molecular Engines Laboratories | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments |
WO2003040369A2 (fr) * | 2001-09-17 | 2003-05-15 | Molecular Engines Laboratories | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments |
CA2417455C (fr) | 2001-09-28 | 2008-01-29 | Brigham Young University | Variants nouveaux de la cyclooxygenase et methodes d'utilisation |
WO2003038087A1 (fr) | 2001-10-04 | 2003-05-08 | Kansai Technology Licensing Organization Co., Ltd. | Promoteur du gene dr5 et promoteur du gene siah-1 |
US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
WO2003031607A1 (fr) * | 2001-10-10 | 2003-04-17 | Bayer Healthcare Ag | Regulation de deshydrogenase/reductase des chaines courtes humaine |
DE60220621T2 (de) | 2001-11-09 | 2008-03-06 | Proteologics, Inc. | Posh Nukleinsäure, Polypeptide und darauf bezogene Verfahren |
AU2002365162A1 (en) | 2001-11-14 | 2003-07-09 | Northwestern University | Self-assembly and mineralization of peptide-amphiphile nanofibers |
CA2468145A1 (fr) * | 2001-11-21 | 2003-05-30 | Japan Science And Technology Agency | Facteurs de transcription de gene de la choree de huntington |
US7151162B2 (en) | 2001-12-06 | 2006-12-19 | The University Of Children's Hospital Of Both Cantons Of Basel | Nuclear protein |
AU2002339697A1 (en) * | 2001-12-19 | 2003-06-30 | Genset S.A. | Gmg-5 polynucleotides and polypeptides and uses thereof |
JP2003245084A (ja) * | 2001-12-20 | 2003-09-02 | Morinaga Milk Ind Co Ltd | 脳梁又は精子の形成不全の診断及び治療に有用な新規遺伝子、並びにその用途 |
DE10163467A1 (de) * | 2001-12-21 | 2003-11-27 | Axaron Bioscience Ag | Protein 24B2 und zugrundliegende DNA-Sequenz |
US6759222B2 (en) | 2002-01-02 | 2004-07-06 | Millennium Pharmaceuticals, Inc. | 14815, a human kinase family member and uses therefor |
WO2003057870A1 (fr) * | 2002-01-07 | 2003-07-17 | Bayer Healthcare Ag | Proteine humaine analogue a la phosphatase de l'acide phosphatidique de type 2 |
AU2003235631A1 (en) * | 2002-01-15 | 2003-07-30 | Bayer Aktiengesellschaft | Human subtilisin/kexin-like convertase |
AU2003205611A1 (en) * | 2002-01-15 | 2003-07-30 | Medigene Ag | Dilated cardiomyopathy associated gene-2 (dcmag-2): a cytoplasmatic inducer of sarcomeric remodeling in cardiomyocytes |
WO2003062429A1 (fr) * | 2002-01-23 | 2003-07-31 | Yamanouchi Pharmaceutical Co., Ltd. | Nouvelle serine protease |
US7371719B2 (en) | 2002-02-15 | 2008-05-13 | Northwestern University | Self-assembly of peptide-amphiphile nanofibers under physiological conditions |
EP1338609A1 (fr) * | 2002-02-21 | 2003-08-27 | MEMOREC Stoffel GmbH-Medizinisch-Molekulare Entwicklung, Köln | Un outre récepteur KDR et son utilisation |
CA2478271A1 (fr) * | 2002-03-05 | 2003-09-18 | Applera Corporation | Proteines transporteuses humaines isolees, molecules d'acide nucleique codant celles-ci, et utilisations associees |
GB2388113A (en) * | 2002-03-06 | 2003-11-05 | Oxford Glycosciences | B-cell malignancy-associated protein |
DK1918386T3 (da) | 2002-03-13 | 2012-01-02 | Genomic Health Inc | Genekspressionsprofiler i biopsier af tumorvæv |
AU2003220913A1 (en) * | 2002-03-19 | 2003-09-29 | Tanabe Seiyaku Co., Ltd. | Novel g protein-coupled recepotrs and genes thereof |
US7527935B2 (en) | 2002-03-19 | 2009-05-05 | Mitsubishi Tanabe Pharma Corporation | G-protein coupled receptor having eicosanoid as ligand and gene thereof |
GB0206684D0 (en) * | 2002-03-21 | 2002-05-01 | Babraham Inst | Novel proteins |
US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
US7329502B2 (en) | 2002-04-25 | 2008-02-12 | The United States Of America As Represented By The Department Of Health And Human Services | ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) |
JP2004041003A (ja) * | 2002-05-17 | 2004-02-12 | Takeda Chem Ind Ltd | 新規タンパク質、そのdnaおよびその用途 |
EP2275118A3 (fr) | 2002-05-29 | 2011-10-19 | DeveloGen Aktiengesellschaft | Proteines specifiques du pancreas |
AU2003237367A1 (en) | 2002-06-03 | 2003-12-19 | Chiron Corporation | Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer |
DK1513934T3 (da) | 2002-06-06 | 2011-05-02 | Oncotherapy Science Inc | Gener og polypeptider relateret til humane coloncancersygdomme |
JP2005535308A (ja) | 2002-06-13 | 2005-11-24 | カイロン コーポレイション | Hml−2ポリペプチド発現用ベクター |
AU2003281626A1 (en) * | 2002-07-22 | 2004-02-09 | Masayoshi Harigai | Novel gene associated with rheumatoid arthritis |
JP4186004B2 (ja) | 2002-08-14 | 2008-11-26 | 独立行政法人産業技術総合研究所 | 新規n−アセチルガラクトサミン転移酵素およびそれをコードする核酸 |
AU2003243151A1 (en) * | 2002-08-16 | 2004-03-03 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
WO2004018518A1 (fr) * | 2002-08-23 | 2004-03-04 | Japan Science And Technology Agency | Peptides antigeniques de tumeur cancereuse solide humains, polynucleotides codant pour ceux-ci et utilisation de ceux-ci |
AU2003250989A1 (en) * | 2002-08-27 | 2004-03-19 | Epigenomics Ag | Method and nucleic acids for the analysis of breast cell proliferative disorders |
US7452969B2 (en) | 2002-08-30 | 2008-11-18 | Licentia Ltd | Neurotrophic factor protein and uses thereof |
CN1703524B (zh) * | 2002-09-30 | 2010-04-07 | 肿瘤疗法科学股份有限公司 | 与人胰腺癌相关的基因和多肽 |
EP1552310A2 (fr) * | 2002-10-17 | 2005-07-13 | EVOTEC Neurosciences GmbH | L'utilisation de la proteine et du gene de la nicotinamide mononucleotide adenylyltransferase 2 (nmnat-2) pour le diagnostique et la therapie des maladies neurodegeneratives |
AU2002952216A0 (en) * | 2002-10-23 | 2002-11-07 | The Walter And Eliza Hall Institute Of Medical Research | Novel therapeutic molecules |
US7554021B2 (en) | 2002-11-12 | 2009-06-30 | Northwestern University | Composition and method for self-assembly and mineralization of peptide amphiphiles |
EP1570080A4 (fr) | 2002-11-15 | 2006-03-01 | Genomic Health Inc | Etablissement de profils d'expressions genetique du cancer a recepteur de facteur de croissance epidermique positif |
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
AU2002953341A0 (en) * | 2002-12-13 | 2003-01-09 | The Walter And Eliza Hall Institute Of Medical Research | A novel phosphoprotein |
AU2003287764B2 (en) * | 2002-12-13 | 2010-01-21 | The Walter And Eliza Hall Institute Of Medical Research | A novel phosphoprotein |
US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
WO2004070025A2 (fr) * | 2003-02-05 | 2004-08-19 | Juan Saus | Nouvelles isoformes de la proteine liant l'antigene de goodpasture et troubles induits par une proteine incorrectement repliee |
EP1445614A1 (fr) * | 2003-02-06 | 2004-08-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Méthodes d'évaluation in vitro de l'état de progression d'un virus HIV chez un individu |
US7074891B2 (en) * | 2003-02-07 | 2006-07-11 | Posco | Leukocyte stimulating peptides |
AU2004213871B9 (en) | 2003-02-20 | 2009-09-03 | Genomic Health, Inc. | Use of intronic RNA to measure gene expression |
WO2004078784A1 (fr) * | 2003-03-04 | 2004-09-16 | Astellas Pharma Inc. | Nouveau gene associe a des conditions fibreuses |
PL378582A1 (pl) | 2003-03-19 | 2006-05-02 | Biogen Idec Ma Inc. | Białko wiążące receptor Nogo |
ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
EP3470535B1 (fr) | 2003-06-24 | 2020-04-01 | Genomic Health, Inc. | Prédiction de probabilité de récurrence de cancer |
US7526387B2 (en) | 2003-07-10 | 2009-04-28 | Genomic Health, Inc. | Expression profile algorithm and test for cancer prognosis |
ATE528397T1 (de) | 2003-08-08 | 2011-10-15 | Perseus Proteomics Inc | Bei krebs überexprimiertes gen |
US20050136434A1 (en) * | 2003-08-12 | 2005-06-23 | Mai Xu | Isolated heat-inducible cell surface protein and hyperthermia-based tumor immunotargeting therapy |
US20070178458A1 (en) * | 2003-09-05 | 2007-08-02 | O'brien Philippa | Methods of diagnosis and prognosis of ovarian cancer II |
TW200517503A (en) * | 2003-09-10 | 2005-06-01 | Japan Science & Tech Agency | Group of genes differentially expressed in peripheral blood cells and diagnostic method and assay method using the same |
EP1667712B1 (fr) * | 2003-10-02 | 2010-07-21 | GlaxoSmithKline Biologicals S.A. | Antigenes de b. pertussis et leur utilisation dans la vaccination |
CA2541006C (fr) | 2003-10-03 | 2015-02-17 | Brigham And Women's Hospital | Ligands de tim-3 et methodes associees |
WO2005040791A2 (fr) * | 2003-10-21 | 2005-05-06 | Bayer Healthcare Ag | Diagnostics et therapeutiques pour maladies liees au recepteur de peptides similaire a la somatostatine et a l'angiogenine (salpr) |
US20050255560A1 (en) * | 2003-11-21 | 2005-11-17 | Zeren Gao | Ztnf11, a tumor necrosis factor |
CA2549164A1 (fr) | 2003-12-05 | 2005-06-23 | Northwestern University | Amphiphiles peptidiques a assemblage automatique et procedes associes d'administration de facteur de croissance |
JP4718490B2 (ja) | 2003-12-23 | 2011-07-06 | ジェノミック ヘルス, インコーポレイテッド | フラグメント化rnaの全般的増幅 |
US20050186577A1 (en) | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
PT3556866T (pt) | 2004-03-02 | 2021-04-30 | Univ Johns Hopkins | Mutações do gene de pik3ca em cancros humanos |
TW200539890A (en) | 2004-03-12 | 2005-12-16 | Brigham & Womens Hospital | Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
WO2005090569A1 (fr) * | 2004-03-24 | 2005-09-29 | The Council Of The Queensland Institute Of Medical Research | Cancer et acides nucleiques et proteines de testicule vsm1 et vsm2, et leurs utilisations |
WO2005095450A2 (fr) | 2004-03-30 | 2005-10-13 | Nsgene A/S | Utilisation therapeutique d'un facteur de croissance, nsg33 |
DK2163650T3 (en) | 2004-04-09 | 2015-11-02 | Genomic Health Inc | Genekspressionsmarkører for prediction of response to chemotherapy |
DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
WO2005118832A2 (fr) * | 2004-06-01 | 2005-12-15 | Bayer Healthcare Ag | Agents diagnostiques et therapeutiques pour des maladies associees a une proteine de type kinase regulee par serum/glucocorticoide (sgkl) |
AU2005258335B2 (en) | 2004-06-24 | 2011-03-17 | Biogen Ma Inc. | Treatment of conditions involving demyelination |
US7587279B2 (en) | 2004-07-06 | 2009-09-08 | Genomic Health | Method for quantitative PCR data analysis system (QDAS) |
US7985831B2 (en) * | 2004-08-05 | 2011-07-26 | Toagosei Co., Ltd. | Crohn's disease antibody epitope peptide and reagent for testing Crohn's disease |
HUE051605T2 (hu) | 2004-11-05 | 2021-03-01 | Nsabp Found Inc | Kemoterápiára adott válasz elõrejelzése génexpressziós markereket alkalmazva |
CA2585561C (fr) | 2004-11-05 | 2018-07-17 | Genomic Health, Inc. | Resultat de groupe esr1, pgr, bcl2 et scube2 comme indicateurs de pronostic de cancer du sein et de prediction de la reponse au traitement |
EP2845865A1 (fr) | 2004-11-12 | 2015-03-11 | Xencor Inc. | Variantes Fc avec liaison altérée en FcRn |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
CA2598251A1 (fr) | 2005-03-04 | 2006-09-14 | Northwestern University | Epitopes angiogeniques de liaison a l'heparine, amphiphiles peptidiques, compositions auto-assemblees et procedes d'utilisation associes |
WO2006120019A2 (fr) * | 2005-05-13 | 2006-11-16 | Centre National De La Recherche Scientifique | Utilisation de nouveau codage genique pour nouvel element de la famille mcm2-8 dans les compositions pharmaceutiques |
MX2008000253A (es) | 2005-07-08 | 2008-04-02 | Biogen Idec Inc | Anticuerpos de sp35 y usos de los mismos. |
WO2007014338A2 (fr) * | 2005-07-26 | 2007-02-01 | Siemens Medical Solutions Diagnostics | Polymorphismes de nucleotides uniques a susceptibilite par rapport a une maladie cardio-vasculaire |
WO2007037601A1 (fr) * | 2005-09-28 | 2007-04-05 | Knu-Industry Cooperation Foundation | Polypeptide inhibant la transmigration de leucocytes ou la croissance et/ou la métastase de cellules cancéreuses, et une protéine de fusion de celui-ci |
EP1790664A1 (fr) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Anticorps monoclonaux contre claudin-18 pour le traitement du cancer |
DE602005023550D1 (de) | 2005-12-14 | 2010-10-21 | Licentia Ltd | Verwendungen eines neurotrophischen Faktors |
EP2044216A2 (fr) * | 2006-07-03 | 2009-04-08 | Exonhit Therapeutics SA | Produits de la transcription spécifiques de la prostate et leur utilisation pour des thérapeutiques et des diagnostics du cancer de la prostate |
EP2066810A2 (fr) * | 2006-09-08 | 2009-06-10 | Corixa Corporation | Procédés, compositions, et kits de détection et de surveillance d'un cancer du colon |
US8076295B2 (en) | 2007-04-17 | 2011-12-13 | Nanotope, Inc. | Peptide amphiphiles having improved solubility and methods of using same |
US8999634B2 (en) * | 2007-04-27 | 2015-04-07 | Quest Diagnostics Investments Incorporated | Nucleic acid detection combining amplification with fragmentation |
GB0805159D0 (en) | 2008-03-19 | 2008-04-23 | Sancho Madrid David | Immune modulation via C-type lectin |
ES2553270T3 (es) * | 2007-07-27 | 2015-12-07 | Immatics Biotechnologies Gmbh | Nuevo epítopo inmunogénico para inmunoterapia |
US7863021B2 (en) | 2007-09-05 | 2011-01-04 | Celera Corporation | Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof |
WO2009034661A1 (fr) * | 2007-09-12 | 2009-03-19 | Toppan Printing Co., Ltd. | Procédé de diagnostic et induction d'une résistance à un virus |
ES2401233T3 (es) | 2007-10-17 | 2013-04-18 | Universidad de Córdoba | Isoformas del receptor tipo 5 de somatostatina humana producidas por tratamiento alternativo y pares de oligonucleótidos para la detección de las mismas por PCR |
HUE024903T2 (en) | 2007-12-26 | 2016-02-29 | Xencor Inc | FC variants with modified binding to FCRN |
GB0803352D0 (en) * | 2008-02-22 | 2008-04-02 | Ntnu Technology Transfer As | Oligopeptidic compounds and uses thereof |
ES2584438T3 (es) | 2008-03-21 | 2016-09-27 | Universiteit Hasselt | Biomarcadores para artritis reumatoide |
EP2315779A2 (fr) | 2008-07-09 | 2011-05-04 | Biogen Idec MA Inc. | Compositions comprenant des anticorps anti-lingo ou leurs fragments |
ATE531383T1 (de) | 2008-07-24 | 2011-11-15 | Nsgene As | Therapeutische verwendung eines wachstumsfaktors, metrnl |
ES2536465T3 (es) | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
CA2758687A1 (fr) | 2008-11-14 | 2010-05-20 | Gen-Probe Incorporated | Compositions, kits et procedes pour la detection d'acide nucleique de campylobacter |
WO2010062960A2 (fr) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | Méthodes de détermination d'une réceptivité à une thérapie par anti-tnfα lors d’une maladie intestinale inflammatoire |
WO2010066018A1 (fr) * | 2008-12-09 | 2010-06-17 | Alethia Biotherapeutics Inc. | Nouveau variant rétroviral endogène humain d’erv3 et utilisations de celui-ci pour diagnostiquer le cancer des ovaires |
WO2010120830A1 (fr) | 2009-04-13 | 2010-10-21 | Northwestern University | Nouvelles structures peptidiques pour la régénération des cartilages et procédés pour les utiliser |
WO2011028952A1 (fr) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes |
ES2802623T3 (es) | 2010-01-27 | 2021-01-20 | Massachusetts Inst Technology | Agentes polipeptídicos técnicamente diseñados para la neutralización dirigida de amplio espectro de la gripe |
AU2011312417B2 (en) | 2010-09-29 | 2015-08-20 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins |
WO2012041328A1 (fr) | 2010-10-01 | 2012-04-05 | Nsgene A/S | Traitement de l'allodynie, de l'hyperalgésie, de la douleur spontanée et de la douleur illusionnelle |
DK2651430T3 (en) * | 2010-12-14 | 2018-08-27 | Hananja Ehf | Biological activity of placental protein 13 |
US9474786B2 (en) | 2011-09-05 | 2016-10-25 | Nsgene A/S | Treatment of allodynia |
WO2013068445A1 (fr) * | 2011-11-09 | 2013-05-16 | Sanofi | Diacylglycérol lipase et applications associées |
PT3489254T (pt) | 2012-04-30 | 2022-12-30 | Biocon Ltd | Proteínas de fusão direcionadas/imunomoduladoras e seus métodos de fabrico |
WO2013167153A1 (fr) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Anticorps utiles dans le diagnostic du cancer |
CN104470541A (zh) | 2012-05-14 | 2015-03-25 | 比奥根艾迪克Ma公司 | 用于治疗涉及运动神经元的疾患的lingo-2拮抗剂 |
WO2013174404A1 (fr) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer |
CN105073776B (zh) | 2012-11-13 | 2019-04-12 | 拜恩科技股份公司 | 用于治疗表达紧密连接蛋白的癌症疾病的制剂 |
WO2014127785A1 (fr) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer |
US9023353B2 (en) * | 2013-03-13 | 2015-05-05 | The Board Of Trustees Of The University Of Arkansas | Anti-(+)—methamphetamine monoclonal antibodies |
WO2014146672A1 (fr) | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer |
CA2908553A1 (fr) | 2013-03-27 | 2014-10-02 | Cedars-Sinai Medical Center | Attenuation ou regression de la fibrose et de l'inflammation par inhibition de la fonction tl1a et des voies de signalisation connexes |
JP7019233B2 (ja) | 2013-07-11 | 2022-02-15 | モデルナティエックス インコーポレイテッド | CRISPR関連タンパク質をコードする合成ポリヌクレオチドおよび合成sgRNAを含む組成物ならびに使用方法 |
WO2015010108A1 (fr) | 2013-07-19 | 2015-01-22 | Cedars-Sinai Medical Center | Signature de la voie de signalisation de tl1a (tnfsf15) |
JP6915987B2 (ja) | 2013-09-25 | 2021-08-11 | シトムクス セラピューティクス,インコーポレイティド | マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法 |
CA2925658C (fr) | 2013-10-01 | 2022-12-06 | Mie University | Antigene contenant une sequence d'interepitope favorisant la presentation d'antigene aux cellules t |
IL302642A (en) | 2014-01-31 | 2023-07-01 | Cytomx Therapeutics Inc | Polypeptide substrates that activate matriptase and U-plasminogen and other cleavable groups, preparations containing them and their uses |
JP2018504400A (ja) | 2015-01-08 | 2018-02-15 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Lingo‐1拮抗薬及び脱髄障害の治療のための使用 |
MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
EP3307070A4 (fr) * | 2015-06-12 | 2019-01-02 | Emory University | Compositions de croissance et de survie pour des cellules capables de produire des anticorps et procédés associés |
CN108138198B (zh) * | 2015-09-04 | 2022-10-28 | 合成基因组股份有限公司 | 为提高的产率而改造的微生物 |
KR20180127416A (ko) | 2016-03-17 | 2018-11-28 | 세다르스-신나이 메디칼 센터 | Rnaset2를 통한 염증성 장 질환의 진단 방법 |
US20200330606A1 (en) * | 2016-03-29 | 2020-10-22 | Valkyrie Therapeutics Inc. | Modulation of structural maintenance of chromosome-1 expression |
US9611297B1 (en) | 2016-08-26 | 2017-04-04 | Thrasos Therapeutics Inc. | Compositions and methods for the treatment of cast nephropathy and related conditions |
US11125757B2 (en) | 2017-05-26 | 2021-09-21 | Emory University | Methods of culturing and characterizing antibody secreting cells |
EP3508499A1 (fr) | 2018-01-08 | 2019-07-10 | iOmx Therapeutics AG | Anticorps ciblant et d'autres modulateurs d'un gène d'immunoglobuline associé à une résistance contre des réponses immunitaires antitumorales et leurs utilisations |
AU2020261435A1 (en) * | 2019-04-26 | 2021-11-25 | Sangamo Therapeutics, Inc. | Engineering AAV |
JP2022538688A (ja) | 2019-07-05 | 2022-09-05 | イオックス セラピューティクス アーゲー | IGSF11(VSIG3)のIgC2に結合する抗体及びその使用 |
WO2021083958A1 (fr) * | 2019-10-29 | 2021-05-06 | Specialites Pet Food | Nouveaux peptides induisant la satiété |
EP4149952A1 (fr) * | 2020-05-12 | 2023-03-22 | Institut Curie | Épitopes néo-antigéniques associés à des mutations sf3b1 |
WO2022008027A1 (fr) | 2020-07-06 | 2022-01-13 | Iomx Therapeutics Ag | Anticorps de liaison à l'igv d'igsf11 (vsig3) et leurs utilisations |
CN117529492A (zh) * | 2021-01-21 | 2024-02-06 | 鹿特丹伊拉斯谟大学医疗中心 | 用于治疗的t细胞 |
US20220260597A1 (en) * | 2021-02-18 | 2022-08-18 | Beren Therapeutics P.B.C. | Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins |
WO2023225602A1 (fr) * | 2022-05-20 | 2023-11-23 | Medikine, Inc. | Polypeptides de liaison au récepteur de l'interleukine-18 et leurs utilisations |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4446240A (en) * | 1981-01-30 | 1984-05-01 | Nerenberg Samuel T | Pancreas specific protein systems |
US5457038A (en) * | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
US6080540A (en) * | 1990-04-20 | 2000-06-27 | Cold Spring Harbor Laboratory | Cloning of mammalian genes in microbial organisms and methods for pharmacological screening |
JP2845623B2 (ja) * | 1990-11-26 | 1999-01-13 | アメリカ合衆国 | 細胞のストレス転写因子 |
US5721352A (en) * | 1991-02-19 | 1998-02-24 | University Of Florida Research Foundation | Entomopoxvirus expression system |
US5840870A (en) * | 1995-12-29 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | Polynucleotides PANC1A and PANC1B associated with pancreatic cancer |
WO1999014234A2 (fr) * | 1997-09-17 | 1999-03-25 | Genentech, Inc. | Stimulation ou inhibition de l'angiogenese et de la cardiovascularisation |
US5912160A (en) * | 1995-08-22 | 1999-06-15 | Thomas Jefferson University | Gab1, Grb2 binding protein, and compositions for making and methods of using the same |
JP3462313B2 (ja) * | 1995-08-24 | 2003-11-05 | キッコーマン株式会社 | 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体dna及び変異型ウリカーゼの製造法 |
US5998165A (en) * | 1995-12-29 | 1999-12-07 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a protein associated with pancreatic cancer |
JP2000511410A (ja) * | 1996-04-29 | 2000-09-05 | ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン | ナンセンス介在rna崩壊の哺乳動物の調節因子 |
US6500934B1 (en) * | 1996-07-24 | 2002-12-31 | Michael Rush Lerner | Bivalent agonists for G-protein coupled receptors |
US5976834A (en) * | 1997-01-09 | 1999-11-02 | Smithkline Beecham Corporation | cDNA clone HNFJD15 that encodes a novel human 7-transmembrane receptor |
US5925521A (en) * | 1997-03-31 | 1999-07-20 | Incyte Pharmaceuticals, Inc. | Human serine carboxypeptidase |
CA2232743A1 (fr) * | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | Tl5, homologue tnf |
WO1998045435A2 (fr) * | 1997-04-10 | 1998-10-15 | Genetics Institute, Inc. | MARQUEURS SECRETES DE SEQUENCE EXPRIMEE (sEST) |
IT1291110B1 (it) * | 1997-04-15 | 1998-12-29 | Istituto Europ Di Oncologia S | Interattori intracellulari e specificita' di legame del dominio eh |
US5948641A (en) * | 1997-05-29 | 1999-09-07 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a metal response element binding protein |
WO1998055620A1 (fr) * | 1997-06-06 | 1998-12-10 | Regeneron Pharmaceuticals, Inc. | Element ntn-2 de la famille des ligands du tnf |
US5932442A (en) * | 1997-09-23 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Human regulatory molecules |
US5972660A (en) * | 1997-10-22 | 1999-10-26 | Incyte Pharmaceuticals, Inc. | Human hydroxypyruvate reductase |
DE19818598A1 (de) * | 1998-04-19 | 1999-10-21 | Metagen Gesellschaft Fuer Genomforschung Mbh | Menschliche Nukleinsäuresequenzen aus Pankreasnormalgewebe |
CA2327317A1 (fr) * | 1998-04-29 | 1999-11-04 | Genesis Research And Development Corporation Limited | Polynucleotides isoles de cellules de la peau et leurs procedes d'utilisation |
US6262249B1 (en) * | 1998-06-23 | 2001-07-17 | Chiron Corporation | Pancreatic cancer genes |
CA2296792A1 (fr) * | 1999-02-26 | 2000-08-26 | Genset S.A. | Sequences marqueurs exprimees et proteines humaines codees |
-
2001
- 2001-01-17 WO PCT/US2001/001351 patent/WO2001055355A1/fr active Search and Examination
- 2001-01-17 AU AU2001241409A patent/AU2001241409A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001340 patent/WO2001055321A2/fr active Search and Examination
- 2001-01-17 CA CA002395666A patent/CA2395666A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001309 patent/WO2001055308A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001333 patent/WO2001055448A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001348 patent/WO2001055368A1/fr active Search and Examination
- 2001-01-17 CA CA002395729A patent/CA2395729A1/fr active Pending
- 2001-01-17 WO PCT/US2001/001343 patent/WO2001055323A2/fr active Search and Examination
- 2001-01-17 CA CA002395699A patent/CA2395699A1/fr active Pending
- 2001-01-17 WO PCT/US2001/001355 patent/WO2001055207A1/fr not_active Application Discontinuation
- 2001-01-17 CA CA002394039A patent/CA2394039A1/fr not_active Abandoned
- 2001-01-17 WO PCT/US2001/001322 patent/WO2001055343A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001327 patent/WO2001055203A1/fr active Search and Examination
- 2001-01-17 AU AU2001250770A patent/AU2001250770A1/en not_active Abandoned
- 2001-01-17 CA CA002395827A patent/CA2395827A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001312 patent/WO2001054733A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001314 patent/WO2001055310A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001326 patent/WO2001055315A2/fr active Search and Examination
- 2001-01-17 CA CA002395734A patent/CA2395734A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001316 patent/WO2001054473A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001325 patent/WO2001055202A1/fr active Search and Examination
- 2001-01-17 CA CA002398877A patent/CA2398877A1/fr not_active Withdrawn
- 2001-01-17 AU AU2001241418A patent/AU2001241418A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001359 patent/WO2001055328A2/fr active Application Filing
- 2001-01-17 CA CA002392438A patent/CA2392438A1/fr not_active Abandoned
- 2001-01-17 AU AU2001241414A patent/AU2001241414A1/en not_active Abandoned
- 2001-01-17 CA CA002395787A patent/CA2395787A1/fr not_active Withdrawn
- 2001-01-17 AU AU2001241412A patent/AU2001241412A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001301 patent/WO2001055303A2/fr not_active Application Discontinuation
- 2001-01-17 CA CA002397407A patent/CA2397407A1/fr not_active Withdrawn
- 2001-01-17 AU AU2001241416A patent/AU2001241416A1/en not_active Abandoned
- 2001-01-17 CA CA002393912A patent/CA2393912A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001302 patent/WO2001055304A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001240 patent/WO2001055302A2/fr not_active Application Discontinuation
- 2001-01-17 WO PCT/US2001/001353 patent/WO2001055206A1/fr not_active Application Discontinuation
- 2001-01-17 CA CA002395403A patent/CA2395403A1/fr not_active Withdrawn
- 2001-01-17 CA CA002395654A patent/CA2395654A1/fr not_active Withdrawn
- 2001-01-17 CA CA002395885A patent/CA2395885A1/fr not_active Withdrawn
- 2001-01-17 CA CA002398411A patent/CA2398411A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001352 patent/WO2001055327A2/fr not_active Application Discontinuation
- 2001-01-17 WO PCT/US2001/001356 patent/WO2001055173A2/fr not_active Application Discontinuation
- 2001-01-17 CA CA002395849A patent/CA2395849A1/fr active Pending
- 2001-01-17 WO PCT/US2001/001349 patent/WO2001054474A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001338 patent/WO2001055367A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001335 patent/WO2001055319A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001344 patent/WO2001055324A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001315 patent/WO2001055311A2/fr active Search and Examination
- 2001-01-17 AU AU2001241415A patent/AU2001241415A1/en not_active Abandoned
- 2001-01-17 CA CA002395872A patent/CA2395872A1/fr not_active Withdrawn
- 2001-01-17 CA CA002395693A patent/CA2395693A1/fr active Pending
- 2001-01-17 WO PCT/US2001/001317 patent/WO2001055201A1/fr active Search and Examination
- 2001-01-17 CA CA002392751A patent/CA2392751A1/fr not_active Abandoned
- 2001-01-17 WO PCT/US2001/001306 patent/WO2001055307A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001336 patent/WO2001055204A1/fr active Search and Examination
- 2001-01-17 CA CA002395858A patent/CA2395858A1/fr not_active Withdrawn
- 2001-01-17 CA CA002393652A patent/CA2393652A1/fr not_active Withdrawn
- 2001-01-17 AU AU2001241408A patent/AU2001241408A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001313 patent/WO2001055200A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001332 patent/WO2001055318A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001357 patent/WO2001055208A1/fr not_active Application Discontinuation
- 2001-01-17 AU AU2001241417A patent/AU2001241417A1/en not_active Abandoned
- 2001-01-17 CA CA002392398A patent/CA2392398A1/fr not_active Abandoned
- 2001-01-17 CA CA002397839A patent/CA2397839A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001342 patent/WO2001059064A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001311 patent/WO2001055309A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001358 patent/WO2001055163A1/fr not_active Application Discontinuation
- 2001-01-17 WO PCT/US2001/001330 patent/WO2001055447A1/fr active Search and Examination
- 2001-01-17 CA CA002395295A patent/CA2395295A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001354 patent/WO2001057182A2/fr not_active Application Discontinuation
- 2001-01-17 WO PCT/US2001/001310 patent/WO2001055387A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001321 patent/WO2001055312A2/fr active Search and Examination
- 2001-01-17 CA CA002395671A patent/CA2395671A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001308 patent/WO2001055364A2/fr active Search and Examination
- 2001-01-17 CA CA002395738A patent/CA2395738A1/fr not_active Withdrawn
- 2001-01-17 CA CA002393618A patent/CA2393618A1/fr not_active Abandoned
- 2001-01-17 CA CA002392428A patent/CA2392428A1/fr not_active Abandoned
- 2001-01-17 AU AU2001241405A patent/AU2001241405A1/en not_active Abandoned
- 2001-01-17 CA CA002395398A patent/CA2395398A1/fr not_active Withdrawn
- 2001-01-17 CA CA002395178A patent/CA2395178A1/fr not_active Withdrawn
- 2001-01-17 CA CA002392422A patent/CA2392422A1/fr not_active Abandoned
- 2001-01-17 CA CA002392450A patent/CA2392450A1/fr not_active Abandoned
- 2001-01-17 CA CA002395724A patent/CA2395724A1/fr active Pending
- 2001-01-17 WO PCT/US2001/001341 patent/WO2001055322A2/fr active Search and Examination
- 2001-01-17 AU AU2001241413A patent/AU2001241413A1/en not_active Abandoned
- 2001-01-17 CA CA002393002A patent/CA2393002A1/fr not_active Withdrawn
- 2001-01-17 CA CA002394841A patent/CA2394841A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001239 patent/WO2001055301A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001328 patent/WO2001055316A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001350 patent/WO2001055350A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001324 patent/WO2001055314A2/fr active Search and Examination
- 2001-01-17 AU AU2001241407A patent/AU2001241407A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001337 patent/WO2001055205A1/fr active Search and Examination
- 2001-01-17 AU AU2001241410A patent/AU2001241410A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001345 patent/WO2001055325A2/fr active Search and Examination
- 2001-01-17 CA CA002392757A patent/CA2392757A1/fr not_active Abandoned
- 2001-01-17 CA CA002395816A patent/CA2395816A1/fr not_active Withdrawn
- 2001-01-17 AU AU2001241406A patent/AU2001241406A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001339 patent/WO2001055320A2/fr not_active Application Discontinuation
- 2001-02-05 AU AU4313701A patent/AU4313701A/xx active Pending
- 2001-02-08 AU AU4141101A patent/AU4141101A/xx active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2398877A1 (fr) | Acides nucleiques, proteines et anticorps | |
CA2441702A1 (fr) | Proteines secretees par l'homme | |
Ben-Shmuel et al. | The role of the cytoskeleton in regulating the natural killer cell immune response in health and disease: from signaling dynamics to function | |
JP2018500019A (ja) | 治療用細胞のコントロールされた活性化または排除のための方法 | |
CA2442777A1 (fr) | Proteines secretees par l'etre humain | |
JP2022526218A (ja) | 汎用ドナー幹細胞及び関連する方法 | |
JP2016514960A (ja) | 改変されたカスパーゼポリペプチドおよびその使用 | |
CA2393616A1 (fr) | Acides nucleiques, proteines et anticorps | |
CN112125973B (zh) | 冠状病毒的特异性抗体或其抗原结合片段 | |
Chang et al. | Dichotomous expression of TNF superfamily ligands on antigen-presenting cells controls post-priming anti-viral CD4+ T cell immunity | |
JP2017523963A (ja) | 移植拒絶の予防及び自己免疫疾患の治療に使用するための単離されたインターロイキン−34ポリペプチド | |
Subra et al. | The balance between CD45RChigh and CD45RClow CD4 T cells in rats is intrinsic to bone marrow-derived cells and is genetically controlled | |
JP4322504B2 (ja) | 肝臓およびリンパ節中の類洞内皮細胞上において、新規なicam−3結合レセプターの結合活性を調節するための方法 | |
Bogunia‐Kubik et al. | From genetic single candidate gene studies to complex genomics of GvHD | |
Jaso-Friedmann et al. | Molecular characterization of a protozoan parasite target antigen recognized by nonspecific cytotoxic cells | |
KR102530161B1 (ko) | 제대혈 혈장 유래의 엑소좀 또는 이의 모방체 및 이의 면역억제 용도 | |
Champagne et al. | Learning to remember: generation and maintenance of T-cell memory | |
Hansson et al. | Immune functions of the vessel wall | |
WO1992011289A1 (fr) | Formation d'antigene | |
Speckmann et al. | Genetic disorders of immune regulation | |
WO1999063084A1 (fr) | Sequences de recepteurs d'antigenes de lymphocytes t specifiques d'arthrosis deformans | |
US20050267025A1 (en) | Compositions and methods for treatment of infectious and inflammatory diseases | |
Ihara et al. | The role of IFN-γ-mediated host immune responses in monitoring and the elimination of Toxoplasma gondii infection | |
TW202313670A (zh) | 識別ha-2抗原之結合蛋白及其用途 | |
WO2023192626A1 (fr) | Méthodes et compositions pour traiter des gliomes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AZWI | Withdrawn application |